Topic: Pegasys
With a prevalence of 2%, it seems as if hepatitis C would not be a disease of great concern. However, chronic hepatitis C is the primary reason for liver transplants, which cost about $280,000 per patient leading to an annual cost of ...
In a case that could have international ramifications, a radiology technician in Florida may have exposed thousands of people to hepatitis C, a potentially deadly virus that attacks the liver. Steven Beumel, a radiology technician at the Mayo Clinic in Jacksonville, reportedly ...
Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. (i) The study also found that Pegetron had ...
Basel, -Newly published study shows that re-treatment with Pegasys? (peginterferon alfa-2a) provides hepatitis C patients with a second chance for a cure Study in Annals of Internal Medicine highlights a new solution for previously-treated hepatitis C patients. New data published today in ...
First Large Study Comparing Leading Hepatitis C Therapies Provides Important Insights to Help Guide Clinical Practice Final results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C, were presented today at the 43rd ...
